Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.

[1]  Michael B. Spring,et al.  Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259) , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Friedlander,et al.  Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment. , 2021, Gynecologic oncology.

[3]  C. Dirksen,et al.  Patient outcomes, patient experiences and process indicators associated with the routine use of patient-reported outcome measures (PROMs) in cancer care: a systematic review , 2020, Supportive Care in Cancer.

[4]  M. Stockler,et al.  Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study. , 2017, The oncologist.

[5]  Q. Wen,et al.  Mental distress, quality of life and social support in recurrent ovarian cancer patients during active chemotherapy. , 2017, European journal of obstetrics, gynecology, and reproductive biology.

[6]  Rocco Casagrande,et al.  Advancing Symptom Science Through Symptom Cluster Research: Expert Panel Proceedings and Recommendations , 2017, Journal of the National Cancer Institute.

[7]  H. Donovan,et al.  Symptom management in women with recurrent ovarian cancer: Do patients and clinicians agree on what symptoms are most important? , 2016, Gynecologic oncology.

[8]  Melanie Calvert,et al.  Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review , 2016, BMJ Open.

[9]  G. Lewith,et al.  Depression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence rates , 2015, BMJ Open.

[10]  M. Stockler,et al.  Symptom Burden and Outcomes of Patients With Platinum Resistant/Refractory Recurrent Ovarian Cancer: A Reality Check , 2014, International Journal of Gynecologic Cancer.

[11]  M. Stockler,et al.  Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit With Chemotherapy for Symptomatic Ovarian Cancer , 2014, International Journal of Gynecologic Cancer.

[12]  M. Stockler,et al.  Symptom Control in Patients With Recurrent Ovarian Cancer: Measuring the Benefit of Palliative Chemotherapy in Women With Platinum Refractory/Resistant Ovarian Cancer , 2009, International Journal of Gynecologic Cancer.

[13]  Declan Walsh,et al.  Symptom clustering in advanced cancer , 2006, Supportive Care in Cancer.

[14]  E. Trimble,et al.  2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  N. Rankin,et al.  Clinical practice guidelines for the psychosocial care of adults with cancer , 2005, Psycho-oncology.

[16]  Hys Ngan,et al.  Carcinoma of the Ovary , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[17]  A. Bottomley,et al.  An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. , 2003, European journal of cancer.

[18]  D. Cella,et al.  Reliability and validity of the functional assessment of cancer therapy-ovarian. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Rex B. Kline,et al.  Principles and Practice of Structural Equation Modeling , 1998 .

[20]  I. Wilson,et al.  Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. , 1995, JAMA.

[21]  D. Osoba,et al.  Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer , 1994, Quality of Life Research.

[22]  D. Osoba.  Lessons learned from measuring health-related quality of life in oncology. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[24]  M. Stockler,et al.  Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer , 2017, Quality of Life Research.

[25]  P. Bentler,et al.  Cutoff criteria for fit indexes in covariance structure analysis : Conventional criteria versus new alternatives , 1999 .